Piper Jaffray Cos. set a $95.00 price target on Bluebird Bio Inc. (NASDAQ:BLUE) in a report released on Thursday morning. The brokerage currently has a a buy rating on the stock.
Other analysts also recently issued research reports about the stock. Maxim Group reaffirmed a buy rating and set a $85.00 target price (down previously from $105.00) on shares of Bluebird Bio in a report on Thursday, August 4th. Leerink Swann reaffirmed a buy rating on shares of Bluebird Bio in a report on Friday, September 9th. Goldman Sachs Group Inc. reaffirmed a buy rating and set a $135.00 target price on shares of Bluebird Bio in a report on Thursday, September 8th. BTIG Research reaffirmed a buy rating and set a $72.00 target price on shares of Bluebird Bio in a report on Wednesday, June 29th. Finally, Jefferies Group reissued a buy rating and issued a $80.00 price objective on shares of Bluebird Bio in a report on Friday, July 8th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and fourteen have given a buy rating to the company’s stock. Bluebird Bio presently has a consensus rating of Buy and an average target price of $91.60.
Shares of Bluebird Bio (NASDAQ:BLUE) opened at 55.50 on Thursday. Bluebird Bio has a 12-month low of $35.37 and a 12-month high of $99.70. The stock’s 50 day moving average is $63.83 and its 200 day moving average is $51.18. The firm’s market cap is $2.06 billion.
Bluebird Bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, August 3rd. The company reported ($1.59) EPS for the quarter, missing the consensus estimate of ($1.44) by $0.15. The company had revenue of $1.55 million for the quarter, compared to the consensus estimate of $2.01 million. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The business’s quarterly revenue was down 68.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.57) EPS. Equities analysts expect that Bluebird Bio will post ($6.19) earnings per share for the current year.
In other Bluebird Bio news, insider Eric Sullivan sold 2,807 shares of the company’s stock in a transaction that occurred on Wednesday, July 20th. The shares were sold at an average price of $45.04, for a total value of $126,427.28. Following the completion of the transaction, the insider now directly owns 4,656 shares in the company, valued at approximately $209,706.24. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 3.50% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in BLUE. Renaissance Technologies LLC purchased a new stake in Bluebird Bio during the first quarter valued at $1,641,000. Wellington Management Group LLP purchased a new stake in Bluebird Bio during the first quarter valued at $51,095,000. Tiverton Asset Management LLC purchased a new stake in Bluebird Bio during the first quarter valued at $3,957,000. AXA boosted its stake in Bluebird Bio by 19.3% in the first quarter. AXA now owns 148,851 shares of the company’s stock valued at $6,326,000 after buying an additional 24,053 shares during the period. Finally, UBS Asset Management Americas Inc. boosted its stake in Bluebird Bio by 0.8% in the first quarter. UBS Asset Management Americas Inc. now owns 157,666 shares of the company’s stock valued at $6,701,000 after buying an additional 1,194 shares during the period.
About Bluebird Bio